Skip to main content

Table 2 Findings of the meta-analyses for hepatitis C virus (HCV) prevalence measures

From: Seroprevalence of hepatitis B and C in Nepal: a systematic review (1973–2017)

Populations at risk Studies Samples HCV prevalence estimates Heterogeneity measures
Total N Total N Mean (%) 95% CI Q (p-value)a τ 2b I2 (confidence limits-%)c Prediction interval (%)d
People who inject drugs 15 3140 45.17 26.34–64.73 1714.1 (< 0.0001) 0.1487 99.2 (99.0–99.3) 0–100
Populations at intermediate risk 12 4998 12.76 5.44–22.47 668.83 (< 0.0001) 0.0486 98.4 (97.9–98.7) 0–59.58
Populations at low risk (general population) 28 972,123 0.68 0.54–0.86 683.44 (< 0.0001) 0.2027 96.0 (95.1–96.8) 0.26–1.75
Populations with liver-related conditions 6 411 11.51 7.73–15.87 7.40 (0.1926) 0.0018 32.4 (0–72.7) 3.48–22.89
Special clinical populations 3 133 1.67 0–5.81 2.79 (0.2473) 0.0022 28.4 (0–92.6) 0–75.38
  1. aQ: the Cochran’s Q statistic is a measure assessing the existence of heterogeneity in HCV prevalence estimates
  2. bτ2: the estimated between-study variance in the double arcsine transformed proportions of the true HCV prevalence estimates. The back-transformed τ2 was not calculated as the methodology to do so is not currently available
  3. cI2: a measure assessing the magnitude of between-study variation that is due to differences in HCV prevalence estimates across studies rather than chance
  4. dPrediction interval: estimates the 95% interval in which the true HCV prevalence in a new HCV study will lie